13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 3 of 6 – SEC Filing

CUSIP No. 253031108

1

Names of Reporting Persons.

Peter Kolchinsky

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

¨

6 Citizenship or Place of Organization.    United States

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7     Sole Voting Power     0
8     Shared Voting Power      5,074,013
9     Sole Dispositive Power     0
10   Shared Dispositive Power  5,074,013
11

Aggregate Amount Beneficially Owned by
Each Reporting Person

5,074,013

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13

Percent of Class Represented by Amount
in Row (11)

9.9%2

14

Type of Reporting Person (See Instructions)

HC, IN

 


2 Represents 5,074,013 shares of the Common
Stock of the Issuer which constitutes approximately 9.86% of the class outstanding. The percentage calculation assumes that there
are currently 51,471,160 outstanding shares of the Common Stock of the Issuer, as advised by the Issuer.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)